POXEL SA (POXEL.PA) Stock Price, Forecast & Analysis
EPA:POXEL • FR0012432516
POXEL.PA Key Statistics, Chart & Performance
The current stock price of POXEL.PA is 0.274 EUR. In the past month the price increased by 12.53%. In the past year, price increased by 30.48%.
POXEL.PA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to POXEL.PA. When comparing the yearly performance of all stocks, POXEL.PA is one of the better performing stocks in the market, outperforming 85.38% of all stocks.
POXEL.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to POXEL.PA. POXEL.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
POXEL.PA Financial Highlights
Over the last trailing twelve months POXEL.PA reported a non-GAAP Earnings per Share(EPS) of -0.26. The EPS increased by 38.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -272.29% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
POXEL.PA Forecast & Estimates
For the next year, analysts expect an EPS growth of -10.48% and a revenue growth -79.58% for POXEL.PA
POXEL.PA Ownership
POXEL.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.35 | 44.21B | ||
| 1AE | ARGENX SE | 28.19 | 44.16B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.038B | ||
| ABVX | ABIVAX SA | N/A | 8.73B | ||
| 2X1 | ABIVAX SA | N/A | 8.73B | ||
| GLPG | GALAPAGOS NV | N/A | 1.911B | ||
| GXE | GALAPAGOS NV | N/A | 1.911B | ||
| IVA | INVENTIVA SA | N/A | 1.108B | ||
| NANO | NANOBIOTIX | N/A | 1.106B | ||
| 6IV | INVENTIVA SA | N/A | 1.075B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About POXEL.PA
Company Profile
Poxel SA is a clinical-stage biopharmaceutical company, which engages in the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as non-alcoholic steatohepatitis (NASH). The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 6 full-time employees. The company went IPO on 2015-02-06. The firm develops drugs with a focus on Type 2 diabetes. The firm aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication. A direct activator of AMPK for the treatment of Type 2 diabetes has started its preclinical development, and other projects in the research phase target diabetes and other metabolic diseases with small molecules that have a disease-modifying mechanism of action. Poxel SAS was spun out from Merck Serono. The firm cooperates with the Laboratory for Fundamental and Applied Bioenergetics, Sumitomo Dainippon Pharma, Joseph Fourier University and Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland, among others.
Company Info
POXEL SA
Imm Le Sunway, 259/261 Avenue Jean Jaures
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 5
Phone: 33437372010
POXEL SA / POXEL.PA FAQ
What does POXEL SA do?
Poxel SA is a clinical-stage biopharmaceutical company, which engages in the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as non-alcoholic steatohepatitis (NASH). The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 6 full-time employees. The company went IPO on 2015-02-06. The firm develops drugs with a focus on Type 2 diabetes. The firm aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication. A direct activator of AMPK for the treatment of Type 2 diabetes has started its preclinical development, and other projects in the research phase target diabetes and other metabolic diseases with small molecules that have a disease-modifying mechanism of action. Poxel SAS was spun out from Merck Serono. The firm cooperates with the Laboratory for Fundamental and Applied Bioenergetics, Sumitomo Dainippon Pharma, Joseph Fourier University and Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland, among others.
What is the current price of POXEL stock?
The current stock price of POXEL.PA is 0.274 EUR. The price increased by 1.48% in the last trading session.
Does POXEL stock pay dividends?
POXEL.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of POXEL stock?
POXEL.PA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is POXEL SA (POXEL.PA) stock traded?
POXEL.PA stock is listed on the Euronext Paris exchange.
When does POXEL SA (POXEL.PA) report earnings?
POXEL SA (POXEL.PA) will report earnings on 2026-04-20, after the market close.